Waksal's Kadmon acquires Three Rivers
This article was originally published in Scrip
Executive Summary
Kadmon Pharmaceuticals, led by former ImClone CEO Dr Samuel Waksal, has acquired Three Rivers Pharmaceuticals, a privately held specialty pharma, for $100 million.
You may also be interested in...
IPO Update: With No New Offerings, Kadmon Steals The Spotlight
Initial public offering activity has been slow as the summer kicks into high gear, but a filing with SEC by Kadmon has peculiarities that promise high drama the likes of which only Sam Waksal could offer.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.